Many cancer center hospital systems are expanding their services across large geographic regions, while cancer care is consolidating around ever enlarging groups.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
